Profil
Sjlva Petrocchi has worked as the Chief Operating Officer at Virostatics Srl since 2007.
Postes actifs de Sjlva Petrocchi
| Sociétés | Poste | Début |
|---|---|---|
Virostatics Srl
 Virostatics Srl Pharmaceuticals: MajorHealth Technology Virostatics Srl is a privately held small pharmaceutical company based in Sassari, Italy. The Italian company is dedicated to discovering and developing novel compounds for the treatment of cancers and viral diseases. The company focuses on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene myc. The team and advisors combine scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development. Virostatics has developed a bioaerosol system to test nebulized drug treatments, inhalers, disinfectants, or devices for virucidal activity in a state-of-the-art biosafety level 3 facility. The company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy, and safety profiles. The company was founded by Franco Lori, who has been the CEO since incorporation. | Directeur des opérations | 01/01/2007 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Virostatics Srl
Virostatics Srl Pharmaceuticals: MajorHealth Technology Virostatics Srl is a privately held small pharmaceutical company based in Sassari, Italy. The Italian company is dedicated to discovering and developing novel compounds for the treatment of cancers and viral diseases. The company focuses on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene myc. The team and advisors combine scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development. Virostatics has developed a bioaerosol system to test nebulized drug treatments, inhalers, disinfectants, or devices for virucidal activity in a state-of-the-art biosafety level 3 facility. The company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy, and safety profiles. The company was founded by Franco Lori, who has been the CEO since incorporation. | Health Technology |
